Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries

References

• Sans S, Kesteloot H, Kromhout D, on behalf of the Task Force. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997;18:1231-48
   Web of Science ®Google Scholar
• Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. Br Med J 1994;308:367-72
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ. An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr 1994;48:305-25
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2007;28:2375-414
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Iglseder B, Moroder T, Staffen W, et al. High prevalence and undertreatment of hypercholesterolaemia in participants in a public stroke prevention programme in Austria. Clin Drug Investig 2005;25:709-17
   PubMed Web of Science ®Google Scholar
• Diamantopoulos EJ, Athyros VG, Yfanti GK, et al., OLYMPIC Study Group. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study. Angiology 2005;56:731-41
   PubMed Web of Science ®Google Scholar
• EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001;22:554-72
   PubMed Web of Science ®Google Scholar
• EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001
   PubMed Web of Science ®Google Scholar
• Kindermann M, Adam O, Werner N, et al. Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007- EUROASPIRE III. Clin Res Cardiol 2007;96:767-86
   PubMed Web of Science ®Google Scholar
• Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract 2007;77:126-33
   PubMed Web of Science ®Google Scholar
• Klingman D, Williams SA, Benner JS, et al. Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J 2005;150:595-601
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI, et al. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, et al. EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154-9
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Delaney JA, Filion KB, et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008;29:2083-91
   PubMed Web of Science ®Google Scholar
• Simons LA, Levis G, Simons J. Apparent discontinuation rates inpatients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-11
   PubMed Web of Science ®Google Scholar
• Hermans MP, Van Mieghem W, Vandenhoven G, et al. Centralized Pan-European survey on the undertreatment of hypercholesterolaemia (CEPHEUS). Acta Cardiol 2009;64:177-85
   PubMed Web of Science ®Google Scholar
• Ferrières J, Gousse ET, Fabry C, et al., on behalf of the French CEPHEUS Investigators. Assessment of lipid-lowering treatment in France – The CEPHEUS study. Arch Cardiovasc Dis 2008;101:557-63
   PubMed Web of Science ®Google Scholar
• Michel G, Muller P. Pan-European survey on the undertreatment of hypercholesterolemia in hypolipidemias (Luxembourg). Bull Soc Sci Med Grand Duche Luxemb 2008;4:509-16
   PubMedGoogle Scholar